Bristol Myers Squibb and SystImmune disclosed early data showing a reduction in breast cancer progression risk from their collaboration. The release provides limited specifics on magnitude, patient population, or trial phase, creating data ambiguity. If forthcoming late-stage readouts corroborate the signal, the partnership could meaningfully bolster BMY's oncology franchise and valuation over time.
Bristol Myers Squibb said its experimental cell therapy for a blood cancer met the primary endpoint in a mid-stage trial. The news could serve as a near-term catalyst for the company’s oncology portfolio and valuation, though detailed safety and durability data remain undisclosed in the snippet.
A federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying approvals for three drugs, including Breyanzi. The decision reopens litigation, heightening regulatory risk and potentially increasing legal costs and exposure for BMS in the near term.
Bristol Myers Squibb announced Houston, Generation Park, as the site for a $2.3 billion, 600,000-square-foot factory to deliver multi-modal manufacturing capabilities. The modular campus will produce small molecules, biologics, and antibody-drug conjugates, expanding domestic capacity and supply resilience. The project supports BMS's $40 billion U.S. investment plan and will initially employ about 500 people with 2,000 construction roles.
Bristol Myers Squibb raised its full-year revenue and profit forecast after a Q2 that beat estimates, driven by Eliquis, Camzyos, and Reblozyl. The results reinforce resilience in Eliquis and momentum from newer drugs, supporting a more favorable outlook and potential valuation upside as demand and margins stabilize.
Investors are eyeing BMY's upcoming quarterly results, with EPS expected at $1.60 on $11.74B revenue. A BofA note keeps the stock favored but trims its price target to $66. The focus on a 3.96% dividend yield ($2.52 annually) adds income appeal as the stock recently gained about 1.7%.
